Results 91 to 100 of about 79,111 (213)

Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly

Clinical Interventions in Aging, 2010
Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta and Hospital, Edmonton, CanadaAbstract: Elderly patients (age≥65 years) with hypertension are at high risk for vascular complications, especially when diabetes is ...
Bodh I Jugdutt
doaj  

Therapeutic potential of the renin angiotensin system in ischaemic stroke [PDF]

, 2016
The renin angiotensin system (RAS) consists of the systemic hormone system, critically involved in regulation and homeostasis of normal physiological functions [i.e.
Arroja, Mariana Moreira Coutinho, McCabe, Christopher, Reid, Emma   +2 more
core   +1 more source

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Chymase as an Important Target to Prevent Organ Damage

Journal of Pharmacological Sciences, 2010
Chymase plays a crucial role in angiotensin II formation in various tissues. Angiotensin II induces gene expression of transforming growth factor (TGF)-β and matrix metalloproteinase (MMP)-9 precursors, and chymase can convert precursors of TGF-β and MMP-
Shinji Takai, Denan Jin, Mizuo Miyazaki
doaj   +1 more source

Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2018
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham, Andersen, Anker, Anker, Borer, Ghosh, Greenberg, Lin, McMurray, McMurray, Metcalfe, Neaton, Packer, Rogers, Rogers, Rogers, Rogers, Solomon, Wei   +18 more
core   +3 more sources

Newly emerging pharmacologic differences in angiotensin II receptor blockers [PDF]

American Journal of Hypertension, 2000
Several angiotensin II receptor blockers (ARB) are currently available for the treatment of hypertension. These drugs share a common mechanism of action-antagonism of angiotensin II AT1 receptors; however, their receptor binding kinetics differ. Candesartan has a higher affinity for the AT1 receptor than all the other ARB.
openaire   +2 more sources

Reduction of Proteinuria in a Patient With Primary Aldosteronism by Angiotensin II Receptor Blocker Administration. [PDF]

JCEM Case Rep, 2023
Rikitake J, Ashida K, Miura M, Nomura M.
europepmc   +1 more source

Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation. [PDF]

Exp Mol Med, 2023
Lee JW, Gu HO, Jung Y, Jung Y, Seo SY, Hong JH, Hong IS, Lee DH, Kim OH, Oh BC.   +9 more
europepmc   +1 more source

Effects of eprosartan on target organ protection

Vascular Health and Risk Management, 2006
Alejandro de la SierraHypertension Unit, Department of Internal Medicine, Hospital Clínic, IDIBAPS, University of Barcelona, SpainAbstract: Hypertension is the most important cardiovascular risk factor for stroke.
Alejandro de la Sierra
doaj  

New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. [PDF]

J Am Heart Assoc, 2023
King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB.   +10 more
europepmc   +1 more source

Structural studies identify angiotensin II receptor blocker-like compounds as branched-chain ketoacid dehydrogenase kinase inhibitors. [PDF]

J Biol Chem, 2023
Liu S, Kormos BL, Knafels JD, Sahasrabudhe PV, Rosado A, Sommese RF, Reyes AR, Ward J, Roth Flach RJ, Wang X, Buzon LM, Reese MR, Bhattacharya SK, Omoto K, Filipski KJ.   +14 more
europepmc   +1 more source